Reverse auction: a potential strategy for reduction of pharmacological therapy cost.
Arq Bras Cardiol
; 105(3): 265-75, 2015 Sep.
Article
en En, Pt
| MEDLINE
| ID: mdl-26200898
ABSTRACT
BACKGROUND:
Polypharmacy is a significant economic burden.OBJECTIVE:
We tested whether using reverse auction (RA) as compared with commercial pharmacy (CP) to purchase medicine results in lower pharmaceutical costs for heart failure (HF) and heart transplantation (HT) outpatients.METHODS:
We compared the costs via RA versus CP in 808 HF and 147 HT patients followed from 2009 through 2011, and evaluated the influence of clinical and demographic variables on cost.RESULTS:
The monthly cost per patient for HF drugs acquired via RA was $10.15 (IQ 3.51-40.22) versus $161.76 (IQ 86.05340.15) via CP; for HT, those costs were $393.08 (IQ 124.74-774.76) and $1,207.70 (IQ 604.48-2,499.97), respectively.CONCLUSION:
RA may reduce the cost of prescription drugs for HF and HT, potentially making HF treatment more accessible. Clinical characteristics can influence the cost and benefits of RA. RA may be a new health policy strategy to reduce costs of prescribed medications for HF and HT patients, reducing the economic burden of treatment.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Propuestas de Licitación
/
Trasplante de Corazón
/
Costos de los Medicamentos
/
Quimioterapia
/
Insuficiencia Cardíaca
Tipo de estudio:
Health_economic_evaluation
/
Observational_studies
Límite:
Adult
/
Aged
/
Humans
/
Middle aged
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
/
Pt
Revista:
Arq Bras Cardiol
Año:
2015
Tipo del documento:
Article
País de afiliación:
Brasil